Learn 3 Ways Anatomic Pathology Drives Advancements in Immuno-Oncology

Advance Your Clinical Trials with Anatomic Pathology Innovations

The future healthcare market landscape is quickly changing, and it is necessary to have a partner who can deliver the services you need. Having a comprehensive anatomic pathology strategy can be crucial to ensuring clinical and commercial success of your product.

In our new infographic, you'll learn:
  • 3 ways anatomic pathology advances immuno-oncology trials
  • How you can experience faster, more collaborative analysis through innovative, leading edge products and molecular services
  • Why an integrated approach is pivotal to ensure success in clinical trials, regulatory approvals and new product launches
As a central laboratory with end-to-end biomarker capabilities across all technology platforms, including genomics and next generation sequencing (NGS), immunohistochemistry (IHC), in situ hybridization (ISH) assays, including FISH, and chromogenic ISH/DDISH, Q2 Solutions has the expertise and experience to employ a broad spectrum of technologies in molecular and anatomic pathology.

Contact us today to learn more about how we use our innovative anatomic pathology solutions and adjunct molecular services to help drug developers optimize outcomes and ensure success in their drug development programs.
Advancing Precision Medicine through Anatomic Pathology

Tissue-based Molecular Testing and Companion Diagnostics

Anatomic Pathology brochure

Comprehensive in-house end-to-end anatomic pathology and adjunct molecular services

Q2SM Oncology Infographic

Providing one global lab partner to support your oncology research from discovery to post-market

Planning and implementing biomarker testing for immuno-oncology trials

Exploring the challenges with the diverse clinical biomarker requirements

Read More